ATE333280T1 - Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen - Google Patents

Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen

Info

Publication number
ATE333280T1
ATE333280T1 AT03703621T AT03703621T ATE333280T1 AT E333280 T1 ATE333280 T1 AT E333280T1 AT 03703621 T AT03703621 T AT 03703621T AT 03703621 T AT03703621 T AT 03703621T AT E333280 T1 ATE333280 T1 AT E333280T1
Authority
AT
Austria
Prior art keywords
treatment
medication
mutation
production
low molecular
Prior art date
Application number
AT03703621T
Other languages
English (en)
Inventor
Vladimir Bykov
Galina Selivanova
Klas Wiman
Original Assignee
Aprea Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200523A external-priority patent/SE0200523D0/xx
Application filed by Aprea Ab filed Critical Aprea Ab
Application granted granted Critical
Publication of ATE333280T1 publication Critical patent/ATE333280T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03703621T 2002-02-21 2003-02-07 Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen ATE333280T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35783102P 2002-02-21 2002-02-21
SE0200523A SE0200523D0 (sv) 2002-02-21 2002-02-21 New compounds

Publications (1)

Publication Number Publication Date
ATE333280T1 true ATE333280T1 (de) 2006-08-15

Family

ID=27759836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703621T ATE333280T1 (de) 2002-02-21 2003-02-07 Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen

Country Status (8)

Country Link
US (1) US7659278B2 (de)
EP (1) EP1476166B1 (de)
AT (1) ATE333280T1 (de)
AU (1) AU2003206329B2 (de)
CA (1) CA2476825C (de)
DE (1) DE60306896T2 (de)
ES (1) ES2269975T3 (de)
WO (1) WO2003070250A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542212A (en) * 2003-03-24 2008-04-30 Aprea Ab Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive WT P53
SE0400708D0 (sv) * 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
ITNA20090047A1 (it) * 2009-07-16 2011-01-17 Adele Bolognese Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
ES2578513T3 (es) * 2010-01-21 2016-07-27 Aprea Ab Solución acuosa que comprende 3-quinuclidinona para el tratamiento de enfermedades hiperproliferativas, autoinmunes y cardiacas
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
EP3806850A2 (de) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Verfahren zur hemmung proliferativer zellen
BR112021005171A2 (pt) 2018-09-20 2021-06-15 Aprea Therapeutics Ab derivados de quinuclidina-3-ona e seu uso em tratamento de câncer
CA3154120A1 (en) 2019-09-18 2021-03-25 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant
WO2022175402A1 (en) 2021-02-18 2022-08-25 Aprea Therapeutics Ab Quinuclidine-3-one derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2002016356A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
DE60209471D1 (de) 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Also Published As

Publication number Publication date
CA2476825C (en) 2011-04-05
EP1476166A1 (de) 2004-11-17
US7659278B2 (en) 2010-02-09
DE60306896D1 (de) 2006-08-31
EP1476166B1 (de) 2006-07-19
CA2476825A1 (en) 2003-08-28
ES2269975T3 (es) 2007-04-01
DE60306896T2 (de) 2007-02-15
US20050090510A1 (en) 2005-04-28
AU2003206329A1 (en) 2003-09-09
AU2003206329B2 (en) 2007-08-09
WO2003070250A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
DE60136473D1 (de) Verwendung von 1-azabicyclo(2.2.2)octan-3-on-derivaten zur behandlung von krebstumoren
ATE333280T1 (de) Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
CY1113039T1 (el) Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
DE60010234D1 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE10337184A1 (de) Substituierte 3-Pyrrolidin-Indol-Derivate
DE60014670D1 (de) Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE602005018390D1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
ATE537832T1 (de) Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivat
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
ATE402710T1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE102004016179A1 (de) Verbindungen zur Behandlung von proliferativen Prozessen
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
EA200501711A1 (ru) Семейство секретируемых белков
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1476166

Country of ref document: EP